Commonwealth Equity Services LLC Has $15.76 Million Stake in Exelixis, Inc. $EXEL

Commonwealth Equity Services LLC lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 43.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 381,659 shares of the biotechnology company’s stock after purchasing an additional 115,395 shares during the period. Commonwealth Equity Services LLC owned 0.14% of Exelixis worth $15,763,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Byrne Asset Management LLC grew its holdings in Exelixis by 129.0% in the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 400 shares in the last quarter. Luminist Capital LLC grew its stake in shares of Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 685 shares in the last quarter. Family Legacy Financial Solutions LLC bought a new position in Exelixis during the second quarter worth about $33,000. Steph & Co. acquired a new stake in Exelixis in the 2nd quarter worth about $44,000. Finally, Hantz Financial Services Inc. raised its stake in Exelixis by 940.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 1,025 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 0.2%

EXEL opened at $44.04 on Friday. The company has a market cap of $11.81 billion, a P/E ratio of 18.58, a PEG ratio of 0.81 and a beta of 0.40. The company’s 50 day moving average is $43.03 and its 200-day moving average is $41.12. Exelixis, Inc. has a 1-year low of $31.90 and a 1-year high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The business had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. During the same period in the prior year, the company earned $0.47 EPS. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, equities analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Transactions at Exelixis

In related news, Director Stelios Papadopoulos sold 100,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the sale, the director owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. This trade represents a 7.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Dana Aftab sold 48,383 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the completion of the transaction, the executive vice president directly owned 664,778 shares of the company’s stock, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 245,235 shares of company stock valued at $10,490,600 over the last quarter. 2.82% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several recent research reports. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Wells Fargo & Company lowered their price objective on Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 21st. Bank of America downgraded Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price for the company. in a research report on Monday, January 5th. Royal Bank Of Canada reissued a “sector perform” rating and set a $45.00 target price on shares of Exelixis in a report on Tuesday, October 21st. Finally, The Goldman Sachs Group assumed coverage on Exelixis in a research note on Wednesday, September 17th. They issued a “buy” rating and a $47.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $45.84.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.